

**Agenda:** To review and evaluate grant applications.

**Place:** Ramada Inn, 1775 Rockville Pike, Rockville, MD 20852.

**Contact Person:** Luigi Giacometti, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5208, MSC 7850, Bethesda, MD 20892, (301) 435-1246.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel.

**Date:** March 12, 1999.

**Time:** 8:30 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Holiday Inn, 5520 Wisconsin Ave., Palladian West, Chevy Chase, MD 20815.

**Contact Person:** Cheri Wiggs, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5194, MSC 7848, Bethesda, MD 20892, (301) 435-1261.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel.

**Date:** March 12, 1999.

**Time:** 3:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call.)

**Contact Person:** Paul K. Strudler, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4100, MSC 7804, Bethesda, MD 20892, (301) 435-1716.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.982, 93.893, National Institutes of Health, HHS)

**Dated:** February 26, 1999.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 99-5411 Filed 3-4-99; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Conjugate Vaccines To Prevent Disease Caused by Nontypeable *Haemophilus influenzae* and *Moraxella catarrhalis*, Particularly Otitis Media

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial Number 08/842,409, entitled "Conjugate Vaccine for Nontypeable *H. influenzae*", filed April 23, 1997 and U.S. Provisional Patent Application Serial Number 60/071,483, entitled "Lipooligosaccharide-Based Vaccine for Prevention of *Moraxella (Branhamella) catarrhalis* Infections in Humans", filed January 13, 1998, to American Home Products Corporation through its Wyeth-Ayerst Laboratory Division, Wyeth-leaderle Vaccines business unit, having a place of business in Madison, NJ. The patent rights in these inventions have been assigned to the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 4, 1999.

**ADDRESSES:** Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Robert Benson, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 267; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** The two patent applications describe conjugates of detoxified lipooligosaccharide (dLOS), isolated from the cellular membrane of either nontypeable *H. influenzae* or *M. catarrhalis*, and a carrier protein, exemplified by tetanus toxoid. These conjugates have been shown to raise bactericidal antibodies against the bacterial strain from which the dLOS was isolated and are also cross-reactive with different strains.

The prospective co-exclusive license will be royalty-bearing and will comply

with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the development of vaccines for the prevention or treatment of diseases in humans caused by infection with nontypeable *H. influenzae* and *M. catarrhalis*.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

**Dated:** February 22, 1999.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 99-5421 Filed 3-4-99; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4445-N-05]

### Notice of Proposed Information Collection: Comment Request

**AGENCY:** Office of the Assistant Secretary for Housing, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

**DATES:** Comments due date: May 4, 1999.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, SW, Room 4176, Washington, DC 20410.

**FOR FURTHER INFORMATION CONTACT:** Marc Harris, Office of Multifamily Housing, telephone number (202) 708-